Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Johnson & Johnson
JNJ
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$253.79
-1.77
-0.69%
Ult. Agg.: Oct 19, 6:08 PM
$253.79
-1.77
-0.69%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 sono stati pubblicati in data mar ott 13th, prima dell'apertura del mercato
Conference call:
La conference call più recente è iniziata alle 8:30 AM, 7 giorni fa
Clicca per vedere il webcast
Johnson & Johnson Financials
Johnson & Johnson (JNJ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.
Priya Nigam
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.
Avi Kapoor
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.
Vandana Singh
QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell about 6%, its steepest one-day drop since April 1, 2025. XLV fell 1.1%.
Piero Cingari
Earnings Scheduled For October 13, 2026
Companies Reporting Before The Bell • Unity Bancorp (NASDAQ:UNTY) is likely to report quarterly earnings at $1.55 per share on revenue of $35.60 million. • JPMorgan Chase (NYSE:JPM) is projected to report quarterly
Benzinga Insights
PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est
Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 analyst estimate. Raises FY2026 sales outlook from $100.800 billion-$101.400 billion to $101.000
Benzinga Newsdesk
